

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **FRONTAGE HOLDINGS CORPORATION**

**方達控股公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1521)**

### **ANNOUNCEMENT UNAUDITED FINANCIAL INFORMATION FOR THE FIRST QUARTER OF 2026**

This announcement is made by Frontage Holdings Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

In addition, this announcement is made by the Company with a view to ensuring that all the shareholders of the Company have equal and timely access to the information of the Company, in light of the announcement by its controlling shareholder, Hangzhou Tigermed Consulting Co., Ltd. (a company listed on the Main Board of the Hong Kong Stock Exchange with stock code: 3347 and on ChiNext market of the Shenzhen Stock Exchange with stock code: 300347), of its unaudited first quarter results of 2026 for the three months ended March 31, 2026 on the Hong Kong Stock Exchange on April 28, 2026.

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders of the Company and potential investors of the following unaudited consolidated financial information of the Group, which were prepared in accordance with the International Financial Reporting Standards based on its unaudited consolidated management accounts: For the three months ended March 31, 2026, the Group recorded a net profit of approximately US\$2.9 million as compared to a net loss of approximately US\$0.9 million for the same period in 2025, on revenue of approximately US\$67.9 million, which represented an increase of 18.9% as compared to approximately US\$57.1 million for the same period in 2025. After excluding share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, and expenses in relation to mergers and acquisitions, the adjusted net profit of the Group was approximately US\$5.0 million, which represented an increase of 212.5% as compared to approximately US\$1.6 million for the same period in 2025.

The net profit for the Group, including a significant increase in adjusted net profit during the first quarter of 2026 compared to the same period last year, was primarily attributable to several factors including: (1) the Group’s year-on-year revenue growth driven by the recovery in market demand, with economies of scale gradually materializing; (2) the continuous and in-depth implementation of lean operation initiatives, which significantly improved operating efficiency and drove a year-on-year increase in both the overall net profit margin and adjusted net profit margin; and (3) the consolidation of Teddy Clinical Research Laboratory (Shanghai) Ltd. (“**Teddy Lab**”) following the completion of its acquisition on March 3, 2026, which also contributed incremental revenue and net profit for the current period.

As at March 31, 2026, the unaudited consolidated net assets of the Group were approximately US\$351.8 million, compared to approximately US\$334.6 million as at December 31, 2025.

**Shareholders and potential investors of the Company should note that the information contained in this announcement is unaudited and has not been reviewed by the Company’s auditors or the audit committee of the board of directors of the Company and may be subject to possible adjustments. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Frontage Holdings Corporation**  
**Dr. Song Li**  
*Chairman*

Hong Kong, April 28, 2026

*As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.*

\* *For identification purpose only*